Evidence map›Paper›PMID 35234358›Full record

ReviewThe Kaohsiung journal of medical sciences2022

Pathophysiology of systemic sclerosis (scleroderma).

Ann-Helen Rosendahl, Katrin Schönborn, Thomas Krieg

2 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Kaohsiung journal of medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 89 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 2 pooled it
19.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06425653 nacompletednot on this map

The Effect of Exercise Program Applied to Patients With Scleroderma on Functional Outcomes: A Randomized Controlled Trial

TypeinterventionalSponsorTrakya UniversityRan2021 to 2021Enrolled44ConditionsScleroderma, Systemic, Scleroderma, Diffuse, Scleroderma, Limited, Hand RheumatismArmsExercise Program
NCT07642297 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

The Potential Pharmacological Role of the TNF-Like Ligand 1A (TL1A) Inhibition in Modulating Systemic Sclerosis (SSc)-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept, In Vitro, Study

TypeobservationalSponsorFondazione Policlinico Universitario Campus Bio-MedicoRan2026 to 2028Enrolled20ConditionsSystemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis, Skin FibrosisArmsTL1A stimulation and inhibition (in vitro)
3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 2 syntheses or guidelines pooled it, 146 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ann-Helen RosendahlTranslational Matrix Biology, University of Cologne, Medical Faculty, Cologne, Germany.ORCID https://orcid.org/0000-0001-7968-0990
Katrin SchönbornTranslational Matrix Biology, University of Cologne, Medical Faculty, Cologne, Germany.ORCID https://orcid.org/0000-0003-1819-8193
Thomas KriegTranslational Matrix Biology, University of Cologne, Medical Faculty, Cologne, Germany.ORCID https://orcid.org/0000-0001-5616-8476
University of Cologne · DE

Funding

Center for Molecular Medicine Cologne (CMMC), University of CologneCologne Excellence Cluster on Cellular Stress Responses in Ageing-Associated Diseases (CECAD)Deutsche ForschungsgemeinschaftEdith Busch Foundation
6 · The paper itself

Abstract

Systemic sclerosis (scleroderma) is an autoimmune-triggered chronic fibrosing disease that affects the skin and many other organs. Its pathophysiology is complex and involves an early endothelial damage, an inflammatory infiltrate and a resulting fibrotic reaction. Based on a predisposing genetic background, an altered balance of the acquired and the innate immune system leads to the release of many cytokines and chemokines as well as autoantibodies, which induce the activation of fibroblasts with the formation of myofibroblasts and the deposition of a stiff and rigid connective tissue. A curative treatment is still not available but remarkable progress has been made in the management of organ complications. In addition, several breakthroughs in the pathophysiology have led to new therapeutic concepts. Based on these, many new compounds have been developed during the last years, which target these different pathways and offer specific therapeutic approaches.

Indexed as

Adaptive ImmunityEnvironmentFibrosisGenetic Predisposition to DiseaseHumansImmunity, InnateScleroderma, Systemicextracellular matrixfibroblastfibrosisinflammation

Identifiers

PMID35234358
PMCPMC11896191
OpenAlexW4214815303

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.